Cerebrospinal fluid biomarkers for Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 18, Issue 2, 2009, Pages 413-417

  Blennow, Kaj ^a   Zetterberg, Henrik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; Biomarker; Cerebrospinal fluid; Diagnosis

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; BMS 299897; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISEASE COURSE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW;

EID: 70350492571     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1177     Document Type: Review

References (28)

1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
2. Blennow K, Hampel H (2003) Cerebrospinal fluid markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613. (Pubitemid 37162569)
3. Peskind ER, Riekse R, Quinn JF, Kaye J, Clark CM, Farlow MR, Decarli C, Chabal C, Vavrek D, Raskind MA, Galasko D (2005) Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 19, 220-225.
4. Blennow K,Wallin A, Hager O (1993) Low frequency of postlumbar puncture headache in demented patients. Acta Neurol Scand 88, 221-223.
5. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-A?42 as diagnostic markers for Alzheimer's disease in clinical practice. Arch Neurol 58, 373-379.
6. Andreasen N, Blennow K (2005) CSF biomarkers for mild cognitive impairment and early Alzheimer disease. Clin Neurol Neurosurg 107, 165-171.
7. Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF Aβ42 levels correlate with amyloid-neuropathology in a polpulation-based autopsy study. Neurology 60, 652-656.
8. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519.
9. Olsson A, Csajbok L, Ost M, Hoglund K, Nyĺen K, Rosengren L, Nellgrd B, Blennow K (2004) Marked increase of β- amyloid(142) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. J Neurol 251, 870-876. (Pubitemid 39005974)
10. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McColloch C, Kohnken R, Padberg F, Pirttila T, Schapiro MB, Rapoport SI,Moller HJ, Davies P, Hampel H (2002) Differential diagnsis of Alzheimer's disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59, 1267-1272.
11. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry 61, 95-102.
12. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, PotterW, Lee VM,Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
13. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308. (Pubitemid 29120227)
14. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234.
15. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin ÅK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek M, Spiru L, Blennow K (2009) Prevalence and prognostic value of cerebrospinal fluid markers of Alzheimer pathology in subjects with subjective cognitive impairment and mild cognitive impairment. The DESCRIPA study. Lancet Neurol, 8, 619-627.
16. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, M van der Flier W, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rośen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Eriksdotter Jonhagen M, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA, 302, 385-393.
17. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K (2003) Cerebrospinal fluid betaamyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds. Dement Geriatr Cogn Disord 15, 169-176.
18. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K (2007) Cerebrospinal fluid β-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 78, 461-464.
19. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E (2007) Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy controls. Dement Geriatr Cogn Disord 24, 118-124.
20. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64, 343-349.
21. Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C (2001) Differential increase in cerebrospinal fluidacetylcholine esterase after treatment with acetylcholine esterase inhibitors in patients with Alzheimer's disease. Neurosci Lett 300, 157-160.
22. Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K, Gallai V (2002) Cerebrospinal fluid levels of biomarkers and activity of acetyl cholinesterase and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci 23, S95-S96.
23. Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N (2007) Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 419, 18-22. (Pubitemid 46694097)
24. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstrom C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A (2007) Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis 12, 255-260. (Pubitemid 350179256)
25. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC (2006) Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602-604. (Pubitemid 43739900)
26. Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, Merchant KM (2003) The gammasecretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]- S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 305, 864-871.
27. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW, on behalf of the PBT2-201-EURO Study Group (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting A? as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7, 779-786.
28. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562.